Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | TNKS | O95271 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | CCNC | P24863 | 5/20 | 0.31 |
| ▸ | CDK8 | P49336 | 5/20 | 0.31 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.30 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.30 |
| ▸ | GSK3A | P49840 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | CDK9 | P50750 | 1/20 | 0.30 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16835493 | 0.89 | GAA (0.33) | OTUD7BGAAL3MBTL1ALDH1A1POLB | |
| SCHEMBL38665546 | 0.84 | OTUD7B (0.39) | OTUD7B | |
| SCHEMBL479513 | 0.82 | — | — | |
| 2-Decanone SCHEMBL12491379 | 0.79 | NAAA (0.37) | ALDH1A1CYP2C9 | |
| SCHEMBL12491380 | 0.79 | NAAA (0.37) | ALDH1A1CYP2C9 | |
| SCHEMBL22729021 | 0.78 | OTUD7B (0.35) | OTUD7BPOLBTDP1 | |
| SCHEMBL17506547 | 0.78 | OTUD7B (0.40) | OTUD7BCYP3A4TNKSCYP2C9TNKS2 | |
| SCHEMBL19659532 | 0.77 | OTUD7B (0.42) | OTUD7BGAACYP3A4TNKSCYP2C9 | |
| SCHEMBL12491086 | 0.76 | OTUD7B (0.36) | OTUD7BCYP3A4TNKSCYP2C9TNKS2 | |
| SCHEMBL24203881 | 0.75 | OTUD7B (0.41) | OTUD7BGAACYP3A4TNKSCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257371-A1 | CYCLIC CYANOENONE DERIVATIVES AS MODULATORS OF KEAP1 | MERCK SHARP & DOHME LLC (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230257371-A1 | CYCLIC CYANOENONE DERIVATIVES AS MODULATORS OF KEAP1 | MERCK SHARP & DOHME LLC (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230257371-A1 | CYCLIC CYANOENONE DERIVATIVES AS MODULATORS OF KEAP1 | MERCK SHARP & DOHME LLC (US) | 2023-08-17 | — | — | US | disclosed |
| US-11725008-B2 | Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-15 | — | — | US | disclosed |
| US-11725008-B2 | Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-15 | — | — | US | disclosed |
| US-11725008-B2 | Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-15 | — | — | US | disclosed |
| EP-4182299-A2 | CYCLIC CYANOENONE DERIVATIVES AS MODULATORS OF KEAP1 | Merck Sharp & Dohme LLC (US) | 2023-05-24 | — | — | EP | disclosed |
| US-20230027126-A1 | ETHANEDIAMINE-HETEROCYCLE DERIVATIVES AS INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-01-26 | — | — | US | disclosed |
| US-20230027126-A1 | ETHANEDIAMINE-HETEROCYCLE DERIVATIVES AS INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-01-26 | — | — | US | disclosed |
| US-11028083-B2 | Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-06-08 | — | — | US | disclosed |
| WO-2012123432-A1 | SEC-HYDROXYCYCLOHEXYL DERIVATIVES AS HSL INHIBITORS FOR THE TREATMENT DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | WO | disclosed |
| WO-2012123468-A1 | NEW AZASPIRODECANONE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | WO | disclosed |
| WO-2012123468-A1 | NEW AZASPIRODECANONE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | WO | disclosed |
| US-20120238594-A1 | AZASPIRODECANONE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-09-20 | — | — | US | disclosed |
| EP-2488493-A1 | SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES | F. Hoffmann-La Roche AG (CH) | 2012-08-22 | — | — | EP | disclosed |
| WO-2011045292-A1 | SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-21 | — | — | WO | disclosed |
| WO-2011045292-A1 | SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-21 | — | — | WO | disclosed |
| US-20110092512-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-21 | — | — | US | disclosed |
| US-20110092512-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-21 | — | — | US | disclosed |
| US-20110092512-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11725008-B2 | Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases | PRMT1, PRMT5, PRMT3 | OTUD7B 1224/4885GAA 4270/4885L3MBTL1 657/4885 |
| US-20120238594-A1 | AZASPIRODECANONE COMPOUNDS | CYP51A1, HSD17B7, NR5A1 | OTUD7B 3459/4885GAA 2396/4885L3MBTL1 4373/4885 |
| US-11028083-B2 | Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases | PRMT1, PRMT5, PRMT3 | OTUD7B 1224/4885GAA 4270/4885L3MBTL1 657/4885 |
| US-20110092512-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | LPL, MGLL, LIPE | OTUD7B 1355/4885GAA 775/4885L3MBTL1 1469/4885 |
| US-20230027126-A1 | ETHANEDIAMINE-HETEROCYCLE DERIVATIVES AS INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASES | PRMT1, PRMT5, PRMT3 | OTUD7B 1224/4885GAA 4270/4885L3MBTL1 657/4885 |
| US-20230257371-A1 | CYCLIC CYANOENONE DERIVATIVES AS MODULATORS OF KEAP1 | KEAP1, NFE2L2, NQO1 | OTUD7B 1535/4885GAA 4109/4885L3MBTL1 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.